LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Trinity Biotech plc (“Trinity” or the “Company”) (Nasdaq: TRIB) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Trinity shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by e-mail at firstname.lastname@example.org.
The investigation concerns whether Chesapeake and certain of its officers and/or directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 4, 2016, the Company announced that it will withdraw its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the advice of the U.S. Food & Drug Administration. The Company also stated that it would reduce spending by nearly 85% and that it would close a Swedish facility, thus eliminating 40 jobs. When this news was announced, shares of Trinity fell in value.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or e-mail us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.